Generally, the importance of IFN-I in the pathogenesis of SLE has been accepted based on the observed IFN-I gene signatures in the majority of patients, as well as success of IFN-blocking therapy in phase III clinical trials (62). Here, IFNA1 is linked to systemic lupus erythematosus.